Insmed (NASDAQ:INSM) Insider Sells $666,982.03 in Stock

Insmed, Inc. (NASDAQ:INSM) insider Michael Alexander Smith sold 6,149 shares of the firm’s stock in a transaction that occurred on Friday, May 22nd. The stock was sold at an average price of $108.47, for a total transaction of $666,982.03. Following the sale, the insider owned 41,613 shares of the company’s stock, valued at $4,513,762.11. This represents a 12.87% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Alexander Smith also recently made the following trade(s):

• On Monday, March 30th, Michael Alexander Smith sold 19,638 shares of Insmed stock. The stock was sold at an average price of $150.98, for a total value of $2,964,945.24.

Insmed Trading Down 3.0%

INSM stock traded down $3.29 during midday trading on Friday, hitting $106.24. 2,432,260 shares of the company’s stock were exchanged, compared to its average volume of 2,749,068. The business has a 50-day simple moving average of $138.55 and a two-hundred day simple moving average of $161.25. The company has a current ratio of 4.47, a quick ratio of 4.10 and a debt-to-equity ratio of 0.80. The stock has a market capitalization of $23.03 billion, a PE ratio of -18.48 and a beta of 0.89. Insmed, Inc. has a 1-year low of $65.56 and a 1-year high of $212.75.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.76) EPS for the quarter, beating the consensus estimate of ($0.90) by $0.14. The business had revenue of $305.96 million for the quarter, compared to analyst estimates of $300.81 million. Insmed had a negative return on equity of 130.11% and a negative net margin of 144.44%.The company’s quarterly revenue was up 229.7% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.42) EPS. On average, sell-side analysts predict that Insmed, Inc. will post -2.52 EPS for the current fiscal year.

Institutional Trading of Insmed

Several hedge funds have recently made changes to their positions in INSM. CIBC Private Wealth Group LLC increased its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 53 shares during the period. CoreCap Advisors LLC purchased a new position in Insmed in the 4th quarter valued at approximately $27,000. SBI Securities Co. Ltd. boosted its position in Insmed by 404.9% in the 3rd quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 166 shares during the period. GraniteShares Advisors LLC acquired a new position in shares of Insmed in the fourth quarter worth $30,000. Finally, Reflection Asset Management acquired a new position in shares of Insmed in the fourth quarter worth $30,000.

Analyst Upgrades and Downgrades

INSM has been the subject of a number of recent analyst reports. Raymond James Financial initiated coverage on shares of Insmed in a research report on Friday, April 10th. They set an “outperform” rating and a $200.00 price target for the company. Stifel Nicolaus upped their price objective on shares of Insmed from $205.00 to $208.00 and gave the stock a “buy” rating in a report on Tuesday, March 24th. HC Wainwright reaffirmed a “buy” rating on shares of Insmed in a research report on Friday, May 8th. Royal Bank Of Canada dropped their target price on shares of Insmed from $220.00 to $205.00 and set an “outperform” rating for the company in a report on Friday, May 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Insmed in a research report on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, Insmed presently has a consensus rating of “Moderate Buy” and a consensus price target of $210.95.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.